Appeal No. 2004-0005 Page 2
Application No. 07/644,361
9. The drug combination of claim 1 wherein the molecule is T Ab 250 or fragments
thereof.
The references relied upon by the examiner are:
Drebin et al. (Drebin I), “Monoclonal Antibodies Reactive With Distinct Domains of the
neu Oncogen-Encoded p185 Molecule Exert Synergistic Anti-Tumor Effect In Vivo,”
Oncogen, Vol. 2, pp. 273-277 (1988)
Drebin et al. (Drebin II), “Monoclonal Antibodies Specific for the neu Oncogen Product
Directly Mediate Anti-Tumor Effects In Vivo,” Oncogen, Vol. 2, pp. 387-394 (1988)
Aboud-Pirak et al. (Aboud-Pirak), Efficacy of Antibodies to Epidermal Growth Factor
Receptor Against KB Carcinoma In Vitro and in Nude Mice,” J. Nat’l Cancer Institute,
Vol. 80, pp. 1605-1611 (1988)
Read, “Hormonal Modulation on HER-2/neu Protooncogene Messenger Ribonucleic
Acid and p185 Protein Expression in Human Breast Cancer Cell Lines,” Cancer
Research, Vol. 50, pp. 3947-3953 (1990)
Documents relied upon by appellants are:
Hudziak et al. (Hudziak ‘692)
(PCT Application) WO 89/06692 July 27, 1989
Alberts et al. (Alberts)(Exhibit B), “Many Catalytic Receptors Are Single-Pass
Transmembrane Glycoproteins with Tyrosine-specific Protein Kinase Activity,” Molecular
Biology, 2d ed. pp. 706-707, 726(1989)
Documents discussed by this merits panel are:
Erickson et al. (Erickson) 6,632,979 Oct. 14, 2003
Shawver et al. (Shawver) 6,123,939 Sep. 26, 2000
Lippman et al. (Lippman) 5,578,482 Nov. 26, 1996
Claim 9 stands rejected under 35 U.S.C. § 112, first paragraph (enablement).
Claims 1 through 8, 10 and 13 through 24 stand rejected under 35 U.S.C. § 103(a) with
the examiner relying upon Drebin I, Drebin II, Aboud-Pirak, and Read as evidence of
obviousness. We reverse the enablement rejection and affirm the obviousness
rejection.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007